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1. Orphan G protein–coupled receptor 
GPR56 and pancreatic β-cell function
Israa Mohammed Al-Amily, Pontus Dunèr, Arvind Soni, 
Olof Asplund, Fateme Safi, Petter Storm, Lief Groop, 
Stefan Amisten and Albert Salehi. 
Department of Clinical Science, Malmö, Division 
of Islets Cell Physiology, Jan Waldenströmsgata 35, 
Building 91, floor 11, SE-205 02 Malmö, Sweden. 
Aim
 The functional role of G-protein coupled receptor 56 
(GPR56) in pancreatic islets and in the pathogenesis 
of diabetes is unclear. We explored the influence of 
GPR56 on insulin secretion in mouse and human 
isolated pancreatic islets.
Material and methods: RNA-seq data confirmed by 
qPCR, confocal microscopy and Western blot in islets 
showed an abundant expression of GPR56 protein in 
β-cells. 
Results
 Diabetic islets showed a reduced GPR56 expression 
which coincided with an attenuated glucose-
stimulated insulin secretion. Long-term culture of 
islets at high glucose concentration reduced GPR56 
expression and islet cell viability. Ablation of Gpr56 
in INS-1 832/13 cells was associated with reduced 
glucose-stimulated insulin secretion, reduced 
cell proliferation, reduced cell viability, reduced 
cell adhesion to collagen III coated matrix and 
increased apoptosis measured by PARP cleavage. 
Down-regulation of Gpr56 in isolated mouse islets 
was associated with disrupted cAMP-production 
and insulin secretory response to glucose.  Further 
functional studies showed that collagen type III 
potentiates glucose-stimulated cAMP-generation 
and insulin release in islets with normal Gpr56 
expression, supporting the idea that collagen type 
III is an agonist for Gpr56. RNA-seq data showed 
a positive correlation of GPR56 expression with 
insulin, WFS1, ABCA3, ATP2A3, TMEM198, RASD1, 
GTF3C, SLC7A4 and C15orf59 and a negative 
correlation with EGFR and VEZT. 
Conclusion
 Taken together, our data demonstrate that the highly 
expressed GPR56 in human and rodent pancreatic 
β-cells plays an important role in β-cell function. We 
propose that GPR56 might be a potential novel target 
for the development of new drugs for the treatment 
of type 2 diabetes.  
2. Pre-meal of whey protein induces 
differential effects on glucose and lipid 
metabolism in subjects with the metabolic 
syndrome
Ann Bjørnshave1,2; Jens Juul Holst3 and Kjeld 
Hermansen1. 
1Department for Endocrinology and Internal Medicine, 
Aarhus University Hospital, Denmark,  
2Danish Diabetes Academy, Odense, Denmark, 
3Endocrinology Research Section, University of 
Copenhagen, Denmark.
Objective
Whey protein (WP) is a potent insulinotropic 
secretagogue. Consumption of WP as pre-meal 
reduces postprandial glycemia after a subsequent 
meal and induces an early insulinemic response. 
No studies have examined, if a pre-meal of WP 
influences the subsequent postprandial lipemia. 
Therefore, we examined if the triglyceride (TG) 
and ApoB-48 responses to the second meal were 
dose-dependently affected by a WP pre-meal prior 
to a fat-rich test meal in subjects with metabolic 
syndrome (MeS). 
Methods
We performed an acute, randomized, cross-over 
study with three arms. At the test day fasting 
data were collected (blood, urine, anthropometric 
measurements and visual analogue scale (VAS)). A 
200ml pre-meal containing 0, 10 or 20 g WP was 
served at -15 min. A fat-rich breakfast (second meal) 
was served at 0 min. The subjects were then observed 
for 360 min after the second meal and VAS was 
carried out every 30 min. 
 
 
Results
Twenty subjects (8 women and 12 men) with MeS 
completed the study. We observed no effects of 
the pre-meal on TG or ApoB-48. The response of 
insulin was increased after consumption of 20 g WP 
compared to 10 g (P<0.001) and placebo (P<0.0001). 
Likewise, the postprandial glucagon response 
was higher after 20 g WP compared to 10 g WP 
(P<0.0001) and 0 g WP (P<0.0001) as pre-meals. 
Consumption of 20 g of WP as pre-meal generated 
a lower blood glucose response (P<0.05) and a 
higher GLP-1 response (p<0.05) compared to 0 g. 
A pre-meal of WP had neither effect on GIP, FFA or 
appetite (VAS). 
Conclusion
Consumption of a pre-meal of WP prior to a fat-rich 
second meal caused a differential impact on lipid and 
glucose responses. No change was observed in the 
postprandial lipid responses, whereas WP stimulated 
insulin and glucagon secretion while blood glucose 
remained low in subjects with MeS. 
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3.The effects of proteins and medium-
chain fatty acids from milk on body 
composition, insulin sensitivity and blood 
pressure in abdominally obese adults 
Mette Bohl1, Ann Bjørnshave, Mette K. Larsen, Søren 
Gregersen, and Kjeld Hermansen
1Department of Endocrinology and Internal Medicine, 
Aarhus University Hospital, Aarhus, Denmark. Mette.
Bohl.Larsen@aarhus.rm.dk
Aim
To investigate whether intake of whey protein 
and butter naturally enriched in medium-chain 
fatty acids (MC-SFAs) (C6-C12) affected the body 
composition, insulin sensitivity, diurnal blood 
pressure (BP) and plasma cholesterol.
Material and methods
A 12-week randomised, double-blinded, intervention 
study was completed in 52 abdominally obese 
adults. Subjects were assigned to one of four dietary 
supplementations: 63 g/day of milk fat with either 
high (8.5 g/day) or low MC-SFA (6.9 g/day) content 
combined with 60 g/day of whey or casein. 
We examined changes in body composition by Dual-
Energy X-ray Absorption scan, insulin sensitivity 
using homeostatic model assessment of insulin 
resistance (HOMA-IR) and Matsuda Index, diurnal 
BP and plasma cholesterol. Two-factor ANOVA was 
used to examine the impact of MC-SFA content and 
protein type. 
Results
We observed that the lean body mass increased by 
981 g (95% CI: 248, 1713; P = 0.010) after high-MC-
SFA compared with low-MC-SFA supplementation. 
Concomitantly, total body fat percentage increased 
by 0.70 percentage point (95% CI: 0.10, 1.31; P = 
0.024) after intake of low-MC-SFA butter compared 
with intake of high-MC-SFA butter. Both changes 
were independent of protein type (P = 0.96 and  
P = 0.99, respectively). We found no difference in 
HOMA-IR, Matsuda Index, diurnal BP or plasma 
cholesterol related to MC-SFA content or protein 
type.
Conclusion
Enhanced intake of MC-SFA increased the lean body 
mass and caused a significantly lower total body fat 
percentage compared with lower intake of MC-SFA. 
Consequently, the composition of dairy fat should 
be considered when evaluating the impact of dairy 
products on body composition.
4. High expression of organic cation 
transporter 3 (oct3) in human bat-like 
adipocytes. Implications for extraneuronal 
norepinephrine uptake
Peter Breining, Steen Bønløkke Pedersen, Arunas Pikelis, 
Lars Rolighed, Elias Immanuel Sundelin, Niels Jessen, 
Bjørn Richelsen 
Department of Endocrinology and Internal Medicine, 
Aarhus University Hospital, Tage-Hansens Gade 2, 8000 
Aarhus C, Denmark. peter.breining@clin.au.dk
Aim
In this study we aimed at examining whether 
OCT3 is present and plays a role in norepinephrine 
(NE) uptake in adipose tissue (AT) and whether 
the presence is correlated to commonly accepted 
thermogenic markers, most notably UCP1. Brown 
adipose tissue (BAT) carries the potential of reducing 
blood glucose and body weight by oxidation of sugar 
and fat in heat production.   
Material and methods
Human subcutaneous AT and deep-neck AT biopsies 
were obtained during neck surgery (thyroid- and 
parathyroid surgery). Gene expression was analyzed 
by qPCR and UCP1 protein was assessed by 
immunohistochemistry. 
The in vitro norepinephrine uptake study was 
performed on isolated brown adipocytes collected 
from the interscapular depot from male Sprague 
Dawley rats. Cells were incubated with 3H-NE, 
propranolol and inhibitors of NE degradation 
enzymes. Selective blockage of OCT3 was obtained 
with corticosterone. 
Results
When comparing deep-neck AT with subcutaneous 
AT from 57 individuals we found that UCP1 
expression was largely confined to the deep-neck 
AT depot. OCT3 was 2.5±0.16 fold higher in the 
deep-neck AT compared to the subcutaneous AT 
and the correlation between UCP1 and OCT3 within 
the deep-neck AT was highly significant. Lastly, we 
were able to reduce NE uptake in isolated brown 
adipocytes by OCT3 blockage.
Conclusion
OCT3 is highly expressed in BAT and selective 
blockage of OCT3 inhibits NE uptake in brown 
adipocytes. This suggests that the brown adipocyte 
has the potential to reduce its own activation 
upon sympathetic stimulation. A self-regulatory 
mechanism is intriguing because it carries a potential 
of a future drug development targeting OCT3 in 
UCP1-rich adipocytes. A pharmacological reduction 
of OCT3 in BAT may increase energy expenditure 
through BAT activation leading to lowering of blood 
glucose and weight loss in type two diabetics.
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5. A reduced-carbohydrate diet high in 
monounsaturated fats in type 2 diabetes: a 
six-month study of changes in metabolism, 
liver- and cardiovascular function 
(reduction)
Eva Marie Gram-Kampmann1, Michael Hecht Olsen, 
Aleksander Krag, Henning Beck-Nielsen
1Department M, Diabetic Research, Kloevervaenget 10, 
6th floor, 5000 Odense C.  
Eva.Gram-Kampmann@rsyd.dk
Aim
Lately, attention has increasingly been directed 
towards low-carbohydrate diets (LCD) for patients 
with diabetes mellitus type 2 (DM2). There 
is confusion amongst researchers and health 
professionals whether a LCD is appropriate diet 
for these patients or not. Recent studies suggest 
that LCM is safe and effective over short-term, with 
significant improvements in weight and glycemic 
control compared to other diets. However, there is 
still a lack of understanding of pathophysiology and 
metabolic changes in reported research.
The aim of this study is to investigate impact of six 
months of LCD with high fraction of fat, compared 
to a regular diabetic diet (RDD), on glycemic control, 
dyslipidemia, fat distribution, and complications 
associated with diabetes. Also, impact on endothelial 
dysfunction, non-alcoholic fatty liver disease 
(NAFLD) associated with diabetes, gut dysbiosis and 
quality of life will be evaluated.
Material and methods
With continuous enrollment, 135 patients with DM2 
will be randomized 2:1 to either a ketogenic LCD or 
RDD for six months. Anthropologic measurements, 
fat distribution evaluated with DEXA, endothelial 
function assessed through ultrasound measured 
flow-mediated vasodilation, retinal vessel geometry, 
NAFLD evaluated through liver biopsy (histology 
and mass spectrometry to evaluate lipidomics, 
metabolomics, proteomics and miRNA) and shear-
wave- and transient elastrography with CAP-scan 
will be conducted before and after six months of 
diet. Also, blood biochemistry associated with 
diabetes and liver disease will be evaluated as well 
as microbiota analyzes with genome (16S)-, meta-
transcription and metabolome-studies. Participants 
quality of life will be assessed through a SF-36 based 
survey. A biobank with stored material (blood, hair, 
sputum, urine and feces) will be established.
Results
Both positive and negative results will be published. 
It is expected that the trial will lead to several 
publications in leading journal in the field of 
Endocrinology and Hepatology. Results will also  
be reported as part of a Ph.D. thesis.
Scientific and social perspectives
By investigating the mechanisms behind the 
consequences of LCD in diabetes, diabetic 
complications and NAFLD, the study is expected  
to impact future guidelines and daily clinical  
practice both in diabetology, hepatology and 
cardiovascular medicine.
6. Large reductions in prescription drug 
used for metabolic syndrome-related 
diseases after gastric bypass surgery: a 
nationwide cohort study
Sigrid Bjerge Gribsholt, MD 1,2, Reimar Wernich 
Thomsen, PhD 2, Dóra Körmendiné Farkas, MSc 2, 
Henrik Toft Sørensen, DMSc 2, Bjørn Richelsen, DMSc 1, 
Elisabeth Svensson, PhD 2
1Department of Endocrinology and Internal Medicine, 
Aarhus University Hospital 
2Department of Clinical Epidemiology, Aarhus 
University Hospital
Aim
After Roux-en Y Gastric Bypass (RYGB) surgery, 
metabolic syndrome-related diseases such as 
diabetes, dyslipidemia and hypertension may 
improve or remit with concomitant reduction or 
discontinuation of associated drugs. While relapse 
of complications may occur, studies with long-term 
follow-up are sparse. Furthermore, little is known 
about the overall prescription drug use before and 
after RYGB. We aimed to evaluate changes over 
time in drug use among patients undergoing RYGB 
surgery and a matched comparison cohort.
Material and methods
Nationwide population-based cohort study, including 
all 9,908 patients undergoing RYGB in Denmark 
during 2006–2010 and 99,080 matched general 
population members. We calculated prevalence 
ratios (PRs) comparing prescription drug use 36 
months after RYGB/index date with use 6 months 
prior to this date (baseline).
Results
 In the RYGB cohort (median age 40 years, 22% 
men), large, sustained decreases (up to 70% 
reduction) occurred for treatment of metabolic 
syndrome-related conditions including any glucose-
lowering drug: 16.5% users at baseline, PR after 3 
years=0.28; 95% confidence interval (CI)=(0.25-
0.31); lipid-modifying drugs: 14.4% users at baseline, 
PR after 3 years=0.50; 95% CI=(0.46-0.55); and 
antihypertensive drugs: 43.2% users at baseline, PR 
after 3 years=0.61; 95% CI=(0.59-0.64). At baseline, 
more RYGB patients used a prescription drug (82.0% 
versus 50.8%), after three years, the PR was 0.93; 
95% CI=(0.92, 0.94) versus PR=1.04; 95% CI=(1.03-
1.05) among comparisons. Use of inhalants for 
obstructive airway diseases [PR=0.79; 95% CI=(0.74-
0.85)] also decreased. Use of neuropsychiatric drugs 
was two-fold higher at baseline in the RYGB cohort 
(22.8% versus 10.9%) and increased similarly after 
RYGB [PR=1.16; 95% CI=(1.10-1.21) versus PR=1.13; 
95% CI=(1.11-1.16)].
Conclusions
 Three years after RYGB surgery, we found large 
reductions in the use of treatment of metabolic 
syndrome-related conditions and inhalants for 
obstructive airway diseases with little indication of 
relapse during this time period. In contrast, frequent 
use of neuropsychiatric drugs did not decrease. 
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7. Hedonic changes in food choices 
following roux-en-y gastric bypass
Thea Toft Hansen*1, Tine Anette Jakobsen*1, Mette 
Søndergaard Nielsen1,2, Anders Sjödin1, Carel le Roux3, 
Julie Berg Schmidt1 
*Contributed equally in conducting the manuscript
1 Department of Nutrition, Exercise and Sports (NEXS), 
Faculty of Science, University of Copenhagen, 
Rolighedsvej 26, Dk-1958 Frederiksberg C;  
2 Odense University Hospital, The Danish Diabetes 
Academy, Sdr Boulevard 29, 5000 Odense C, Denmark;  
3 Imperial College, London 
Phone: +45 28708653 or +45 35334754,  
E-mail: tha@nexs.ku.dk 
Aim
Roux-en-Y gastric bypass surgery (RYGB) seems 
to lead to a shift in food choices in the direction of 
less energy-dense foods, which may be explained by 
decreased hedonic drive to consume highly palatable 
foods. Literature on hedonic changes in food choices 
following RYGB is reviewed with the hypothesis 
that changes in food preferences can be ascribed to 
post-surgical alterations in hedonic appetite control. 
This review summarizes literature examining post-
operative changes in mechanisms contributing to 
hedonic drive (food preferences, reinforcing value of 
food, dopamine signaling and activity reward-related 
brain regions). Dopamine signaling and activity 
in reward-related brain regions are discussed as 
potential mechanisms involved in how foods are 
preferred and how they reinforce behavior differently 
following RYGB.
 
 
 
Material and methods
An automated literature search using the Medical 
subheadings (MeSH terms) Gastric bypass and 
appetite in PubMed was conducted on the 13th of 
January 2016 identifying 11 papers fulfilling the 
criteria.
Results
Questionnaires indicate that patients decrease food 
seeking of highly palatable foods after RYGB. Results 
from behavioral tests are conflicting with one study 
suggesting that the rewarding value of chocolate 
candy is decreased following RYGB, while an interim 
analysis from our own group using an ad libitum 
buffet meal show no changes in food choices. Studies 
on brain activity and signaling in dopaminergic 
pathways in response to highly palatable food cues 
indicate that these are altered after RYGB; however 
results are not entirely consistent.
Conclusion
The majority of studies discussed, indicate that 
RYGB changes several factors that collectively 
lead to a decreased hedonic drive to consume 
highly palatable, energy dense foods. This may 
play an important role in changing food choices 
towards a diet with a lower energy density. Yet, 
human behaviors are complex, and sociological and 
psychological factors are very likely to affect eating 
behavior outside an experimental setting.
8. Epigenome-wide changes in dna 
methylation and risk of cardio-metabolic 
disease in 9-14 years old offspring of gdm 
women and controls
Line Hjort1,2,3, Louise G Grunnet1, Anders H Olsson1, 
David Martino3, Frank B Hu4, Cuilin Zhang5, Richard 
Saffery3,6, Sjurdur F Olsen7 and Allan A Vaag1.
1Dept. of Endocrinology (Diabetes and Metabolism), 
Copenhagen University Hospital, Denmark 
2Danish Diabetes Academy, Odense, Denmark 
3Cancer and Disease Epigenetics Group; Murdoch 
Children’s Research Institute (MCRI); Royal Children’s 
Hospital; Parkville, VIC Australia  
4Harvard Medical and Public Health school, Boston, 
USA 
5National Institute of Child Health and Human 
Development, Bethesda, USA 
6Dept. of Paediatrics, Melbourne University, Parkville, 
Australia 
7Centre for Fetal Programming, Statens Serum Institut, 
Copenhagen, Denmark
Aims
Offspring of women with Gestational Diabetes 
Mellitus (GDM) are at increased risk of developing 
Type 2 Diabetes later in life. A growing number of 
studies implicate the time in utero as playing a key 
role in regulating later diabetes risk with potential 
effects mediated by epigenetic variation in the 
offspring at birth. However, whether these epigenetic 
changes are persistent, and are associated with risk 
of cardio-metabolic disease in later life, remains 
unknown. Using an epigenome-wide approach, we 
aimed to investigate DNA methylation profiles in 
blood from 9-14 year old offspring of GDM women 
relative to matched non-GDM controls.
 
Methods
We recruited 608 GDM and 623 control offspring 
from the Danish National Birth Cohort. DNA from 
92 GDM offspring and 94 controls were analyzed for 
genome-wide DNA methylation profiles using the 
Infinium HumanMethylation450 BeadChip platform. 
Results
BMI, height, total body fat percentage, fasting 
plasma glucose and insulin levels were higher among 
GDM offspring compared to controls (p≤0.001). We 
identified 76 significant differentially methylated 
positions (DMPs) between the groups at the genome-
wide level (adjusted p≤0.05). DMPs were primarily 
located within exons, with the majority showing 
lower methylation in GDM offspring (92%), and 
several have previously been reported associated 
with diabetes and ageing.
Conclusions
Offspring of GDM pregnancies present prediabetes 
traits and altered DNA methylation profiles in blood 
at age 9-14 years. This supports a role for DNA 
methylation in fetal programming of metabolic 
health and suggests that that GDM has long-term 
effects on offspring epigenetic profile. Stable marks 
may serve as interesting sites in investigation of 
causal relation to the increased T2D risk later in life. 
Validation studies are in progress in the entire cohort 
of 1,240 children. 
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9. Neonatal vitamin d3 and risk of type 1 
diabetes in danish children
Ramune Jacobsen, Peder Frederiksen, Berit L. Heitmann
Research Unit for Dietary Studies, The Parker Institute, 
Frederiksberg Hospital, Nordre Fasanvej 57, 2000 
Frederiksberg, Denmark; e-mail: ramune.jacobsen@
regionh.dk
Aim
The aim of the study was to assess the association 
between the levels of vitamin D3 in neonatal blood 
(25(OH)D3) and the later risk of type 1 diabetes 
(T1D) in Danish children up to age of 18 years. 
Material and methods
A case-cohort study was designed. A random sub-
cohort of 3600 individuals born in Denmark in the 
period 1981-2002 was selected from the Danish Civil 
Registration system.  Additionally, a random sample 
of 1100 individuals developing T1D until age of 18 
years and diagnosed until 2012 was selected from 
the Danish Childhood Diabetes Register. Neonatal 
25(OH)D3 levels were measured using the punches 
from the Dried Blood Spots (PKU cards), which are 
stored at the National Neonatal Specimen Bank 
and contain the blood samples routinely taken 
from the heel of all new-born babies in Denmark. 
The statistical analysis were based on quintiles of 
25(OH)D3 levels in the sub-cohort, and weighted 
Cox regression models were run adjusting for birth 
weight, gestational age, mother’s age, diabetes 
diagnosis, ethnicity, education and job situation. 
Results
In all, 3 778 individuals had valid vitamin D3 
measurements, 912 were diagnosed with T1D. 
Neonatal serum 25(OH)D3 concentrations in 
individuals from the random sub-cohort varied from 
0,0 to 130,3 nmol/l with the median (25-75%ile-
range) being 23.8 (13.5-36.7) nmol/l. Gestational 
age per week: HR (95%CI)=0.96 (0.93-1.00); 
mother’s diabetes diagnosis versus non-diagnosis: 
HR (95%CI)=1.67 (1.20-2.33); and ethnicity: HR 
(95%CI) for non-Western  versus Danes=0.39 
(0.25-0.61) - were associated with the T1D risk. 
There was no association between levels of neonatal 
serum 25(OH)D3 and the T1D risk: HR (95%CI) for 
1st, 2nd, 4th and 5th, versus 3rdquintile were: 0.85 
(0.66-1.10), 0.95 (0.75-1.22), 0.86 (0.67-1.10), 0.96 
(0.76-1.21), respectively.  
Conclusion
Our large-scale study shows that vitamin D3 around 
time of birth is not associated with the risk T1D up to 
age 18 years. 
10. Effects of 12 weeks high dose vitamin 
D3 treatment on insulin sensitivity, beta 
cell function, and metabolic markers 
in patients with type 2 diabetes and 
vitamin D insufficiency – a double-blind, 
randomized, placebo-controlled trial
Ulla Kampmann1, Leif Mosekilde, Claus Juhl, Niels 
Moller, Britt Christensen, Lars Rejnmark, Louise 
Wamberg, Lotte Ørskov
1 Department of Endocrinology and Internal Medicine, 
Aarhus University Hospital, Nørrebrogade 44, 8000 
Aarhus C, ulla@opstrup.dk
Aim
Vitamin D insufficiency is common in subjects with 
type 2 diabetes. Observational studies suggest that 
vitamin D plays a role in the pathogenesis of type 2 
diabetes. However, results of intervention studies 
have been inconsistent. We investigated the effects 
of improving vitamin D status on insulin sensitivity, 
insulin secretion, and inflammatory markers in 
patients with type 2 diabetes.
Materials and Methods
A double blind, randomized, placebo controlled trial 
was conducted. Sixteen patients with type 2 diabetes 
and hypovitaminosis D were recruited. Eight patients 
received colecalciferol and (280μg daily for 2 weeks, 
140μg daily for 10 weeks) and 8 patients received 
identical placebo tablets for 12 weeks. Before and 
after intervention, patients underwent an IVGTT, 
a hyperinsulinemic euglycemic clamp, assessment 
of baseline high-frequency insulin pulsatility, 
glucose-entrained insulin pulsatility, DXA scans, 
24-Hour-Ambulatory Blood Pressure Monitorings, 
and fasting blood samples. 
Results
Serum-25(OH) vitamin D and serum-1,25(OH)2 
vitamin D increased significantly after 12 weeks 
in the intervention group (p = 0.01, p = 0.004). 
Serum-25(OH) vitamin D was also significantly 
higher in the vitamin D group compared to the 
placebo group (p = 0.02) after intervention. 
Although no significant changes in insulin sensitivity, 
inflammation, blood pressure, lipid profile, or HbA1c 
were found, we observed borderline (p between 
0.05 and 0.10) improvements of insulin secretion, 
in terms of c-peptide levels, first phase incremental 
AUC insulin and insulin secretory burst mass.
Conclusions
Improvement in vitamin D status does not improve 
insulin resistance, blood pressure, inflammation 
or HbA1c, but might increase insulin secretion in 
patients with established type 2 diabetes.
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11. The effects of eucaloric saturated and 
polyuunsaturated high fat diets on insulin 
sensitivity and metabolism in healthy men
Annemarie Lundsgaard1,2, Jørgen  Frank  Pind  
Wojtaszewski1, Erik  Richter1, Bente Kiens1
1Section of Molecular Physiology, Department of 
Nutrition, Exercise and Sports, Faculty of Science, 
University of Copenhagen  
Universitetsparken 13, 2100 Copenhagen, Denmark.  
2Danish Diabetes Academy 
amlundsgaard@nexs.ku.dk
The effect of dietary fatty acid content and quality on 
insulin sensitivity and molecular metabolism is not 
clear, and well controlled dietary intervention studies 
in healthy subjects are required. 
The Aim of the present study was to evaluate 
peripheral and hepatic insulin sensitivity, health 
related parameters and molecular metabolism before 
and after eucaloric 6 weeks high-fat diets (64 E% 
fat). The intervention was divided in two, one diet 
enriched in long-chain saturated fatty acids (SFA) 
and one diet enriched in polyunsaturated fatty acids 
(PUFA).
Materials and methods
18 untrained healthy men (age 33±1 years, BMI 
26±1, VO2peak 39±1 ml∙min-1∙kg-1) completed the 
study (n=9 in each group). The hyperinsulinemic-
euglycemic clamp was applied and [6.6-2H2] glucose 
was infused to evaluate hepatic glucose production. 
Skeletal muscle and subcutaneous adipose tissue 
biopsies were obtained.
Results
The glucose infusion rate and insulin-stimulated 
leg glucose uptake were not changed after the high 
fat diets. Fasting respiratory exchange ratio (RER) 
was markedly decreased after both interventions 
(p<0.001), but the increase in RER with insulin 
(i.e. metabolic flexibility) was intact compared 
to baseline. The basal hepatic glucose Ra was 
lower after both interventions (p<0.01), and the 
suppression of glucose production with insulin was 
not changed. Fasting plasma insulin (p<0.01) and 
plasma triacylglycerol (p<0.01) was lower after 
both interventions, while total cholesterol (p<0.01) 
and LDL cholesterol (p=0.06) concentration was 
lower after PUFA. In skeletal muscle, the capacity 
for FA uptake was increased after the interventions, 
evidenced by increased cluster of differentiation 
36 (CD36), fatty acid transport protein 1 (FATP1) 
and fatty acid transport protein 4 (FATP4) protein 
content, concomitant with a lowering of TBC1 
domain family member 1 (TBC1D1) protein,  
which might play a role for the observed increase  
in fat oxidation.
Conclusion
A high-fat diet is not detrimental to insulin action, 
as long as subjects are in energy balance, and 
polyunsaturated fat may have beneficial effects on 
lipoprotein metabolism. 
12. effect of intake of extra protein high 
in ketogenic amino acids (e.G. Leucine) 
together with resistance training for four 
month in elderly individuals. Implications 
for physical function, muscle and bone.
Jesper L Mehlsen, Kristina Nørgaard, Niels Møller, Bente 
L Langdahl, Steen B Pedersen, Bjørn Richelsen.
Endocrinology and Internal Medicine, Aarhus University 
Hospital, Tage-Hansens gade 2, 8000 Aarhus c 
jlme@clin.au.dk
Aim 
The objective of this study was to determine whether 
chronic supplementation of whey protein with extra 
leucine improves physical function such as six-
minute walk distance and four-meter gait speed and 
whether this treatment affects the body composition 
in elderly men and women. 
Materials and methods
The study was a 4 month randomized single blinded 
placebo controlled intervention study, including 47 
women and 10 men between 60-85 years of age with 
osteopenia (t-score<-1.0 by DEX scan).  The subjects 
were assigned to receive daily supplementations 
of 45.8 g whey protein with 6.14 g leucine (n=24), 
45.9 g soy protein with 3.1 g leucine (n=23) or 
an isocaloric placebo product with maltodextrin 
and no protein (n=10). Concurrently with the 
supplementation, the subjects conducted a guided 
resistance-training program three times a week.  
Body composition was determined by DEX scan 
before and after the intervention.
Results
Six-minute walk distance was increased significantly 
in the whey group with high leucine (p<0.05) 
compared to the soy group (low leucine) by 3.5%. 
There was, however, no effect on four-meter gait 
speed. Surprisingly, the ratio of LBM/FM was 
significantly increased in the soy group compared 
to the whey group (p<0.05). Weight and BMI were 
increased within the whey and placebo groups (all 
p<0.05), and LBM was increased within the soy 
group (p<0.05). Plasma glucose, insulin and HOMA 
index increased within the whey group (all p<0.05) 
without any changes in the two other groups.
Conclusion
Four month of whey protein supplementation with 
extra leucine and concurrently resistance training 
significantly increased six-minute’ walk distance in 
elderly individuals. Surprisingly, the ratio of LBM/
FM increased significantly only in the soy protein 
group with the lower amount of leucine  
(3.1 g vs 6.1 g daily). 
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13. changes in the hedonic component of 
taste does not predict food preferences 
assessed by an ad libitum meal 6 month 
post roux-en-y gastric bypass or sleeve 
gastrectomy surgery
Mette Søndergaard Nielsen1,2, Simone Rasmussen1, 
Wender Bredie3, Christian Ritz1, Anders Sjödin1, Julie 
Berg Schmidt1
1Department of Nutrition, Exercise and Sports, Faculty of 
Science, University of Copenhagen,  
2The Danish Diabetes Academy,  
3Department of Food Science, Faculty of Science, 
University of Copenhagen.
Aim
The effect of Roux-en-Y gastric bypass (RYGB) and 
Sleeve gastrectomy (SG) surgery on food preferences 
has never been investigated by measures of direct 
behavior. A proposed mechanism for the effect of 
surgery on food preferences includes post-operative 
changes in the hedonic component of taste. Using 
an ad libitum buffet meal we investigated if RYGB 
and SG surgery leads to changes in food preferences, 
and whether this was associated with post-operative 
changes in fat perception and sweet taste.
Material and methods
Forty-one diabetic (n=10) and non-diabetic (n=31) 
subjects (BMI 45±7kg/m2) completed a sensory 
preference test and consumed an ad libitum buffet 
meal before and 6 month after RYGB (n=31) or SG 
(n=10). Ratings of preference for sweet taste and fat 
perception were registered for 4 variations of apple 
juice (5, 10, 15 and 20g sucrose/L) and 5 variations of 
cocoa milk (0.4, 1.5, 3, 10 and 38% fat) on a 9-point 
hedonic scale. An index was calculated as the sum of 
log-concentration multiplied with the rating. Twenty 
food items organized equally into the following food 
categories: high-fat-savory (HFSA), low-fat-savory 
(LFSA), high-fat-sweet (HFSW) and low-fat-sweet 
(LFSW) were represented on the buffet. The subjects 
were instructed to eat ad libitum and according to 
their preferences. Relative energy intake from each 
category was calculated. 
Results
Relative intake (% of total energy intake) from each 
of the 4 food categories did not change following 
surgery (all P>0.20). Postoperative changes in fat 
perception and sweet taste were not associated with 
changes in relative intake of fat (HFSA: R2=0.06; 
HFSW: R2=0.04; HFSA and HFSW: R2=0.08; 
all P≥0.29) or sweet (HFSW: R2=0.04; LFSW: 
R2=0.04; HFSW and LFSW: R2=0.07, all P≥0.19) 
from the buffet meal. Food preferences assessed at 
the buffet meal did not differ between surgery groups 
(all P≥0.30) or between diabetes and non-diabetics 
(all P≥0.18), justifying combining data in one pooled 
analysis.
Conclusion
Our data do not support the hypothesis that 
RYGB and SG surgery leads to changes in food 
preferences, or that post-operative changes in the 
hedonic component of taste predicts changes in food 
preferences.  
14. Low Carbohydrate Diet Reduces the 
Glycaemic Response to Glucagon in 
Patients with Type 1 Diabetes
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Background and aims
Dual hormone pump treatment with insulin and 
glucagon reduces the risk of mild hypoglycaemia. 
However, the efficacy of glucagon to elevate plasma 
glucose (PG) when liver glycogen stores are partly 
depleted is unknown. 
This two-way crossover randomized clinical study 
investigated the effect of low-dose glucagon to 
restore PG from mild hypoglycaemia in patients 
on high (HCD) (≥250 g daily) vs low (LCD) 
carbohydrate diets (≤50 g daily).
Materials and methods
Ten patients with insulin pump treated type 1 
diabetes (median±SD age 48±10 years, HbA1c 
6.9±2.7 %, diabetes duration 22.5±7 years, and BMI 
24.5±1.8 kg/m2) randomly completed one week 
of HCD and one week of LCD. Each week ended 
with a study visit, where fasting patients received 
subcutaneous insulin bolus estimated to reduce 
PG to 3.0 mmol/l. When PG ≤ 3.9 mmol/l, 100 µg 
glucagon was given subcutaneously followed by 500 
μg glucagon after two hours.
Results
The PG time course after glucagon differed between 
HCD vs LCD (repeated measurement ANOVA: time 
x studyvisit, p=0.003). HCD had higher peak rises 
after both first (2.7±0.4 vs 1.3±0.3 mmol/l, p=0.003) 
and second glucagon bolus (5.6±0.5 vs 4.1±0.3 
mmol/l, p=0.006). Similar, HCD had higher PG level 
two hours after the first (4.1±0.3 vs 3.1±0.2 mmol/l, 
p=0.01) and the second glucagon bolus (8.5±0.6 vs 
5.9±0.5 mmol/l, p=0.005). However, the difference 
of the area under the glucose curve between the first 
and second glucagon dose after HCD was similar to 
LCD (366±53 vs 254±58, p=0.06).  Further, the time 
to peak was similar after the first (31.9±2 vs 28.1±2.3 
min, p>0.05) and second glucagon bolus (48.1±14 vs 
44±14 min, p>0.05).  
Conclusion
We conclude that LCD may impair the treatment 
effect of glucagon on mild hypoglycaemia. However, 
the first glucagon dose may not additionally reduce 
the LCD induced effect on a second glucagon bolus. 
Thus, patient’s carbohydrate intake should be 
assessed when low doses of glucagon are used in 
open loop and maybe also in closed loop settings.
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15. Steno abc: advanced carbohydrate 
counting with or without an automated 
bolus calculator in type 1 diabetes
Signe Schmidt*, Eva Hommel, Dorte Vistisen, Kirsten 
Neergaard, Thomas Almdal, Kirsten Nørgaard
*Hvidovre University Hospital, Dept. of Endocrinology, 
Kettegård Allé 30, 2650 Hvidovre, Denmark 
Signe.Schmidt@regionh.dk
Background
Advanced carbohydrate counting (ACC) improves 
metabolic control in patients with type 1 diabetes 
(T1D).
Aim
The aim of this study was to test whether 
concomitant use of an automated bolus calculator 
(ABC) would induce further improvements.
Material and Methods
In a 12-month, randomized, parallel group, open-
label, single-centre, investigator-initiated clinical 
trial, we enrolled ACC-naïve adults with multiple 
daily insulin injections-treated T1D and HbA1c 
64-100 mmol/mol. In a 1:1 ratio, participants were 
randomized to receive training in either ACC using 
mental calculations (MC-group) or ACC using an 
ABC (ABC-group) during a 3.5-hour group training 
course. For 12 months post training, patients 
attended a specialized diabetes centre quarterly. The 
primary outcome was change in HbA1c from baseline 
to 12 months. 
Results
Between August 2012 and September 2013, 168 
participants (96 men, 72 women) were recruited 
and randomly assigned to the MC-group (n=84) and 
the ABC-group (n=84). Drop-out rates were 23.8% 
and 21.4%, respectively (p=0.712 (between-group 
difference)); 130 participants completed the study. 
Baseline HbA1c was 75±9 mmol/mol in the MC-
group and 74±8 mmol/mol in the ABC-group. At 12 
months, change in HbA1c was significant within both 
groups; MC-group -2 mmol/mol/year (95% CI -4 to 
-1, p=0.017) and ABC-group -5 mmol/mol/year (95% 
CI -6 to -3, p<0.0001). However, HbA1c reductions 
were significantly greater in the ABC-group 
(p=0.033). No episodes of severe hypoglycaemia 
were reported.
Conclusion
T1D patients initiating ACC obtained significantly 
greater HbA1c reductions when guided by an ABC.
16. High fat diet-induced changes of 
mouse hepatic transcription and enhancer 
activity are reversed by subsequent weight 
loss
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Gordon L. Hager2, Jay H. Chung3, Lars Grøntved1,*
1Department of Biochemistry and Molecular Biology, 
University of Southern Denmark,  
5320 Odense M, Denmark.  
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Epigenetic factors have been suggested to play an 
important role in metabolic memory by trapping 
and maintaining initial metabolic changes within 
the transcriptional regulatory machinery1,2. 
However, there is considerable controversy 
regarding the permanency of these changes after 
intervention.  The aim of this study was to identify 
hepatic epigenetic- and transcriptional changes 
associated with intake of a high fat diet (HFD) 
followed by subsequently weight loss. We fed 
mice (C57BL6) a HFD for seven weeks followed by 
additional five weeks of chow to identify HFD-me-
diated changes to the hepatic transcriptional 
program. Mice fed a HFD displayed increased 
fasting insulin levels, hepatosteatosis and major 
changes in hepatic gene transcription associated 
with modulation of H3K27ac at enhancers, but 
no major changes in chromatin accessibility, 
indicating that HFD regulated gene transcrip-
tion is exclusively controlled by alteration of 
pre-established enhancer activity. After return to 
the same body weight as chow fed control mice, 
the fasting insulin, glucose, and hepatic TG levels 
of the formerly obese mice were restored. More-
over, HFD-regulated H3K27Ac and mRNA levels 
returned to similar levels as chow fed mice. These 
data provide strong evidence, that the transcrip-
tion regulatory landscape in liver induced by HFD 
is highly dynamic and can be reversed by weight 
loss. This provides hope for efficient treatment 
of early obesity-associated changes to hepatic 
complications by simple weight loss intervention 
without significant persistent reprograming of the 
liver transcriptome.
1 Leung, A., Trac, C., Du, J., Natarajan, R. & Schones, D. E. Persistent 
chromatin modifications induced by high fat diet. The Journal of 
biological chemistry, doi:10.1074/jbc.M115.711028 (2016).
2 Horvath, S. et al. Obesity accelerates epigenetic aging of human liver. 
Proceedings of the National Academy of Sciences of the United States of 
America 111, 15538-15543, doi:10.1073/pnas.1412759111 (2014).
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17. Adipose Tissue Storage Enzymes and 
Postprandial Lipemia in Type 2 Diabetes
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Michael D. Jensen2, Søren Nielsen1
Department of Endocrinology and Internal Medicine, 
Aarhus University Hospital 
Endocrine Research Unit, Mayo Clinic 
The Danish Diabetes Academy
Background and aims
Ectopic lipid storage is associated with insulin 
resistance and development of type 2 diabetes. In 
accordance with the adipose tissue expandability 
hypothesis, this may be a consequence of impaired 
postprandial adipose tissue storage capacity. 
Therefore, we measured enzyme activity of enzymes 
involved in adipose tissue lipid storage: Lipoprotein 
lipase (LPL) (hydrolyzes triglyceride (TG) from 
lipoproteins), acyl-CoA synthetase (ACS) (activation 
of fatty acids for anabolic or catabolic pathways) and 
diacylglycerol acetyltransferase (DGAT) (final step in 
TG synthesis). We hypothesized, that men with type 
2 diabetes have lower activity of storage enzymes, 
which may contribute to their greater postprandial 
lipemia 
Materials and methods
11 men with type 2 diabetes and 10 weight-matched 
healthy men were included.  Postprandial LPL, 
ACS and DGAT enzyme activity was measured in 
abdominal and femoral adipose tissue biopsies 
five hours after an oral fat tolerance test (FTT). 
Postprandial VLDL-TG storage was measured after a 
bolus of ex-vivo labeled [3H]-triolein VLDL-TG.
 
 
Results
No differences were observed between type 2 diabetic 
and healthy men in LPL activity [Abdominal: 0.7 
(0.4-1.5) vs 0.7 (0.4-1.3) (p=0.75); Femoral: 0.6 
(0.4-1.6) vs 0.6 (0.5-1.0) (p=0.87) μmol FFA/g/
hr], ACS activity [Abdominal: 60±14 vs 69±21 
(p=0.34); Femoral: 49±9 vs 65±26 (p=0.09) pmol/
mg lipid/min] or DGAT activity [Abdominal: 7.7±2.1 
vs 7.7±2.4 (p=0.94); Femoral: 5.3±1.6 vs 6.6±3.3 
(p=0.31) pmol/mg lipid/min]. LPL (p=0.04), ACS 
(p=0.03) and DGAT (p<0.01) activity was greater 
in abdominal compared to femoral adipose tissue. 
Abdominal ACS activity was inversely related to 
the peak total TG (R2=0.29, p<0.01) and VLDL-TG 
(R2=0.66, p<0.01) plasma concentration after the 
FTT. Femoral LPL activity (R2=0.57, p<0.02) was 
inversely related to the peak plasma VLDL-TG after 
the FTT. Postprandial VLDL-TG storage rate was 
not associated with the activity of any of the storage 
enzymes.
Conclusion
Men with type 2 diabetes have preserved 
postprandial adipose tissue storage enzyme activities, 
which, therefore, do not explain their increased 
ectopic lipid storage. However, LPL and ACS activity 
may affect the extent of postprandial lipemia and 
the lipid amount available for ectopic fat storage 
irrespectively of type 2 diabetes.
18. Association between sugar intake and 
coronary event risk in the malmö diet and 
cancer cohort
Khadija Warfa, Isabel Drake, Peter Wallström, Gunnar 
Engström, Emily Sonestedt1
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Aims
Previous studies have suggested that a high intake of 
sugar-sweetened beverages is positively associated 
with the risk of a coronary events. However, few 
studies have examined the association between 
sucrose (i.e., sugar) and incident coronary events. 
The aim of the present study was, therefore, to 
examine the associations between sucrose intake and 
coronary event risk in a large cohort.
Materials and methods
We performed a prospective analysis on 26,190 
individuals (62% women) free from diabetes and 
without a history of cardiovascular diseases from the 
Swedish population-based Malmö Diet and Cancer 
cohort. Over an average of 17 years of follow-up, 
2,493 incident cases of coronary events (fatal or 
non-fatal myocardial infarction or death attributable 
to ischemic heart disease) were identified from 
registers. Sucrose intake was obtained from an 
interview-based diet history method, including 7-day 
records of prepared meals and cold beverages and 
a 168-item diet questionnaire covering other foods. 
Cox proportional hazards regression was used to 
model the association between sucrose and coronary 
event risk adjusted for gender, age, energy intake, 
dietary method, season, smoking, waist, alcohol 
consumption, physical activity, educational level, 
intake of fruit and vegetables, whole grains, coffee, 
fermented milk, meat, and fish. A restricted cubic 
spline was computed to examine the shape of the 
association between sucrose intake and coronary 
event risk. 
Results
Participants who consumed more than 15% of 
their energy intake (E%) from sucrose (five percent 
of this population) had a 37% (95% CI=13-66%) 
increased risk of a coronary event compared with 
the lowest sucrose consumers (<5 E%). In addition, 
we observed a non-linear association indicating that 
the risk increased above the median intake (8.2 E%), 
and no benefit of having a lower sucrose intake was 
observed.
Conclusion
 The results indicated that high sucrose consumption 
is associated with an increased risk of a coronary 
events. 
2726 Danish Diabetes Academy Diet, Diabetes and the Metabolic Syndrome
Danish Diabetes Academy
Funded by the Novo Nordisk Foundation
